Advertisement
Advertisement

FDA Approves Generic Formulation of Didanosine (ddI) Delayed Release Capsules

December 3, 2004


This article is part of The Body PRO's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

The Food and Drug Administration (FDA) today (December 3, 2004) approved a generic formulation of Didanosine (ddI) Delayed Release capsules, 200 mg, 250 mg, and 400 mg for use in combination with other antiretroviral agents in the treatment of HIV-1 infection in adults. The product, manufactured by Barr Laboratories, Inc. of Pomona, NY will be available for use within the United States and foreign countries.

It is the first approval in the United States of a generic antiretroviral product to treat HIV/AIDS.

Didanosine (ddI) is a generic version of the already approved Videx EC Delayed-Release Capsules manufactured by Bristol Myers Squibb. It is a delayed-release capsule, taken once daily.




This article was provided by AIDSinfo. Visit the AIDSinfo website to find out more about their activities and publications.
 

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.